Photo: Polina Tankilevitch | Pexels
Vaccines for cancer, cardiovascular and autoimmune diseases, and other conditions may be ready by 2030 if accelerated progress, which has surged in the past three years, is maintained with a high level of investment. Researchers say 15 years’ worth of progress has been “unspooled” in 12 to 18 months thanks to Covid vaccine development. Dr Paul Burton, chief medical officer of pharmaceutical company Moderna, believes the firm will be able to offer personalized cancer vaccines against multiple different tumor types in as little as five years, multiple respiratory infections could be covered by a single injection, and mRNA therapies could be available for rare diseases for which there are currently no drugs. The US Food and Drug Administration has granted expedited regulatory review for Moderna’s experimental mRNA vaccine for RSV and for its personalized cancer vaccine. Pfizer has begun recruitment for a late-stage clinical trial of an mRNA-based influenza vaccine, and has its sights set on other infectious diseases, including shingles, in collaboration with BioNTech.
|
|
More:
